Kidney Graft Function Under the Immunosuppression Strategies

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

Also called NCT01817322

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 140 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01817322
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01817322. Randomized; no masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2013-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Kidney Graft Function Under the Immunosuppression Strategies
Acronym
MyLowCsA
Condition
Chronic Renal Disease
Intervention (Drug)
Standard Dose of Myfortic and Reduced Dose of Myfortic
Intervention (Drug)
Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group
Intervention (Drug)
Basiliximab injected both control group and experimental group
Lead sponsor
Samsung Medical Center (class: other)

Record details

Record id
cardio:ct-nct01817322
Content hash
eae0cea0cad3b4ddbd2f7b0c9b3b1e84beb04a128a690d22b4dfe512838e2d06